Category: Suggested Reading

All Podcast Categories
S3-E43.5 - The Future of Combination Agents in NASH Therapy

S3-E43.5 – The Future of Combination Agents in NASH Therapy

First author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). This episode explores the future of combination agents in NASH Therapy.

S3-E43.4 - Optimizing Combination Agents

S3-E43.4 – Optimizing Combination Agents

First author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). This episode explores the optimization of combination agents in NASH Therapy. The conversation takes a broader look into the strategies behind developing and pairing combination agents and the role they can potentially play in a wider scope of treatment.

S3-E43.3 - Science Partnerships and NASH Trials

S3-E43.3 – Science Partnerships and NASH Trials

First author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). In this conversation, the panel continues its discussion around strategies for deciding which agents to combine in trials, along with a plea for larger BioPharma companies to pursue science partnerships with smaller companies even if there are no strong commercial bonds between the companies. In the end, discussion of the ongoing LEGEND trial gives panelists a chance to express different opinions about combination agent strategy.

S3-E43.2 - Finding the Right Combinations in NASH Therapy

S3-E43.2 – Finding the Right Combinations in NASH Therapy

n Season 3 Episode 43, first author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). In this conversation, the group explores the role of NITs as the prime diagnostic tool alongside combination agents, and discusses practical issues surrounding patient management and theoretical ones in deciding which agents to combine for trials.

S3-E43.1 - Combination Agents for Fibrotic Regression

S3-E43.1 – Combination Agents for Fibrotic Regression

In Season 3 Episode 43, first author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). The theme of the episode is to explore the role of combination agents for NASH therapy over time. This opening conversation focuses on the design and execution of the triple-agent study, and how it may contribute to fibrotic regression.

S3-E42.1 - Allied Health and Patient Empowerment for NAFLD

S3-E42.1 – Allied Health and Patient Empowerment for NAFLD

Louise Campbell hosts this week’s NASH Tsunami and talks about the role of allied health professionals and patient empowerment in developing a NAFLD pathway. In this conversation, Jörn Schattenberg discusses a paper he co-authored that aims to guide multisectoral action on NAFLD through a societal approach.

S3-E42 - Allied Health and Patient Empowerment for NAFLD

S3-E42 – Allied Health and Patient Empowerment for NAFLD

Louise Campbell hosts this week’s NASH Tsunami while host, Roger Green, finds a new surf vacationing on the Jersey Shore. In this episode, the role of allied health professionals and patient empowerment is discussed in the context of a Sustainable Development Goal Framework for NAFLD.

S1-E2 — What’s Behind The New AACE Fatty Liver Guidelines?

S1-E2 — What’s Behind The New AACE Fatty Liver Guidelines?

Drs. Mary Rinella, Zobair Younossi and Diana Barb join co-hosts Dr. Ken Cusi and Roger Green to explore the new AACE Fatty Liver guidelines. Learn about the epidemiology and research behind the guidelines and what they recommend for endocrinologists, primary care physicians and allied health professionals when screening, diagnosing and managing Type 2 Diabetes patients for Fatty Liver disease.

S3-E40.3 - Importance of Early Diagnosis in Lean NASH

S3-E40.3 – Importance of Early Diagnosis in Lean NASH

Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on why early diagnosis is so important when dealing with Lean NASH.

Experience Nudge Learning!
Interested in a new way of learning?